ResMed Inc. ($RMD) Stock Forecast: Down 6.1% Today

What is ResMed Inc.?

ResMed (RMD) is a global leader in digital health, focusing on cloud-connected devices for people with sleep apnea and other chronic diseases. The company has been known for its innovative solutions in the healthcare sector.

Why is ResMed Inc. going down?

RMD stock is down 6.1% on Oct 31, 2025 13:40

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

RMD Price Chart

RMD Technical Analysis

RMD News

ResMed ( RMD ) Q1 Earnings and Revenues Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of +2.41% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2782002/resmed-rmd-q1-earnings-and-revenues-beat-estimates

Seeking Clues to ResMed ( RMD ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

https://www.zacks.com/stock/news/2780002/seeking-clues-to-resmed-rmd-q1-earnings-a-peek-into-wall-street-projections-for-key-metrics

Do Options Traders Know Something About ResMed Stock We Don't?

Investors need to pay close attention to RMD stock based on the movements in the options market lately.

https://www.zacks.com/stock/news/2777963/do-options-traders-know-something-about-resmed-stock-we-dont

Trending Today

ZCash ($ZEC) Crypto Forecast: Down 13.5% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Binance Coin ($BNB) Crypto Forecast: Up 5.4% Today

ResMed Inc. Price History

27.07.2024 - RMD Stock was up 5.0%

• ResMed's stock surged by 12% in the quarter, reflecting strong investor confidence in the company's growth prospects.
• Positive outlook from William Blair further boosted investor sentiment towards ResMed, indicating a favorable future trajectory for the stock.
• Despite an executive selling shares worth over $200k, the overall market sentiment remained positive, suggesting that investors were not significantly deterred by the insider selling.
• ResMed's consistent outperformance over the past decade, with an average annual return of 15.63%, has solidified its position as a strong investment choice, attracting more investors to the stock.

25.09.2024 - RMD Stock was up 6.1%

• ResMed's strong Q1 financial results, fueled by growing demand for its sleep devices and masks, have driven a positive trend in its stock.
• The company's solid overall performance, evident in improved margins and surpassing financial projections, has instilled confidence among investors.
• Analysts consider ResMed a resilient player in the medical technology industry, underpinned by strong fundamentals, which likely attracted more investors and contributed to the upward movement in the market.

05.02.2025 - RMD Stock was down 2.9%

• Today, ResMed's stock experienced a notable bearish trend, potentially due to investors engaging in profit-taking following a substantial 25.6% increase over the past year. Despite the success of the AirSense platform fueling positive momentum, market participants may have chosen to secure their profits, resulting in downward pressure on the stock price.

25.09.2024 - RMD Stock was up 5.9%

• ResMed (RMD) experienced a strong bullish movement today following the release of its Q1 earnings.
• The company surpassed both earnings and revenue estimates, indicating strong financial performance and market confidence.
• Investors likely responded positively to the results, showing optimism about ResMed's growth potential and ability to deliver consistent value to shareholders.
• The market movement could be attributed to the market's favorable reaction to ResMed's solid performance and optimistic outlook for future growth.

24.03.2025 - RMD Stock was up 5.1%

• ResMed reported stellar third-quarter fiscal 2025 results, surpassing earnings and revenue estimates, showcasing strong execution across all business areas.
• The appointment of Salli Schwartz as Chief Investor Relations Officer could have instilled confidence in investors, signaling a focus on transparent communication and investor relations.
• The positive market reaction indicates that investors are optimistic about ResMed's future prospects and growth trajectory, driven by robust financial performance and strategic leadership appointments.

31.09.2025 - RMD Stock was down 6.1%

• Despite ResMed (RMD) beating earnings and revenue estimates for Q1, the stock experienced a bearish movement.
• The options market activity suggests that there might be some uncertainty or negative sentiment surrounding the stock.
• Investors may be reacting to factors beyond the quarterly performance, such as future growth projections or market conditions.
• The bearish movement could also be influenced by profit-taking activities following a period of positive performance.

08.03.2025 - RMD Stock was down 5.1%

• ResMed recently introduced NightOwl, an FDA-approved home sleep apnea test in the US. Nevertheless, the stock faced a decline in the market.
• Speculation from sources suggests the stock may not see further growth despite positive earnings estimate revisions.
• Investor expectations for ResMed's performance could have driven a sell-off of the stock following news of the successful product launch.

04.07.2025 - RMD Stock was up 4.0%

• ResMed (RMD) exceeded expectations in Q2 earnings, outperforming projections for both earnings per share and sales.
• Analysts have raised their forecasts for the company following the strong earnings report, signaling confidence in its future performance.
• Surpassing estimates for Q4 earnings and revenue reinforces ResMed's market position and indicates potential for further growth.
• The uptick in ResMed's stock price reflects its robust financial results and positive outlook for the future.

31.00.2025 - RMD Stock was down 5.8%

• ResMed (RMD) reported strong Q2 earnings and revenue surpassing expectations, but the stock faced a bearish trend.
• The stock's decline post-achieving a 52-week high could be attributed to profit-taking, causing a temporary decrease in price.
• Some investors are uncertain about the sustainability of ResMed's growth, leading them to sell shares despite positive financial performance.
• The bearish movement might also stem from broader market shifts or sector rotations, with investors temporarily diverting attention from healthcare stocks.

31.00.2025 - RMD Stock was down 8.3%

• Despite beating Q2 earnings and revenue estimates, the stock experienced a bearish movement.
• Investors might have been expecting even higher earnings and revenue figures, leading to a sell-off after the announcement.
• The market may have reacted negatively to guidance or other forward-looking statements made by the company's management during the earnings call.
• Overall market conditions or external factors could have influenced the bearish sentiment towards ResMed (RMD) despite its positive financial performance.

10.02.2025 - RMD Stock was up 5.2%

• The bullish movement in RMD can be attributed to the strong sales performance of its mask and device products, showcasing the company's ability to meet market demand effectively.
• The success of ResMed's cloud-connected AirSense platform has also played a significant role in driving investor confidence and contributing to the stock's impressive rally.
• Despite concerns about increasing debt levels, the market seems to be focusing more on the company's product innovation and industry outperformance, leading to the bullish movement in the stock.

07.03.2025 - RMD Stock was up 5.7%

• Resmed's stock saw a rise following the successful launch of NightOwl, a home sleep apnea test, in the US.
• The FDA-cleared diagnostic tool is expected to boost the company's market presence and revenue prospects in the sleep apnea sector.
• Investor reactions indicate faith in Resmed's cutting-edge products and its capacity to meet the increasing need for in-home healthcare remedies.